Antivirals and Biologics for Broader Coverage Against Human Coronaviruses DOI Open Access

Mia Outteridge,

Christine M. Nunn,

Kevin M. Devine

и другие.

Опубликована: Дек. 12, 2023

Coronaviruses (CoVs) are enveloped positive-sense single-stranded RNA viruses with a genome 27-31kbases in length. Critical genes include the spike (S), envelope (E), membrane (M), nucleocapsid (N) and 9 accessory open reading frames encoding for non-structural proteins (NSPs) that have multiple roles replication cycle immune evasion (1). There 7 known human CoVs most likely appeared after zoonotic transfer, recent being SARS-CoV-2 responsible Covid-19 pandemic. Antivirals been approved by FDA use against such as Paxlovid can potentially target successfully inhibit main protease (MPro) activity of CoVs, however alternative proteomes encoded CoV genomes closer genetic similarity to each other, suggesting antivirals could be developed now future CoVs. New introductions humans inevitable unpredictable. Therefore, new required control not only next outbreak, but also 4 common (229E, OC43, NL63, HKU1) circulate frequently contain sporadic outbreaks severe (SARS-CoV, MERS SARS-CoV-2). The current study found emerging antiviral drugs, Paxlovid, proven SARS-CoV-2. Other drugs which potential other still within clinical trial yet available public use. Monoclonal antibody (mAb) treatment vaccines reduce mortality hospitalisation rates, they Spike protein whose sequence mutates drifts. is applicable targeting HCoVs these well conserved sequences among Thus, there need readily treatments globally all improve preparedness outbreaks. Here we discuss research contributing transmission, including outbreak. aim was identify features antivirals, biologics scientific, political, economic health strain caused future.

Язык: Английский

Subclinical SARS-CoV-2 Infections and Endemic Human Coronavirus Immunity Shape SARS-CoV-2 Saliva Antibody Responses DOI Open Access
Tonia L. Conner, Emilie Goguet, Hannah Haines-Hull

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Май 22, 2024

SUMMARY This study characterized antibody responses induced by COVID-19 mRNA vaccination and SARS-CoV-2 infection in saliva. Utilizing multiplex microsphere-based immunoassays, we measured saliva anti-SARS-CoV-2 spike IgG, IgA, secretory IgA 1,224 samples collected from healthcare workers the Prospective Assessment of Seroconversion between August 2020 through December 2022. By spring 2022, most individuals had detectable spike-specific antibodies Longitudinal measurements nucleocapsid IgG revealed that detected was driven subclinical clinically-evident infections, rather than alone. In contrast, strongly exhibited improved durability with hybrid immunity. Baseline levels to endemic human coronaviruses positively correlated post-vaccination levels. provides insights for development vaccines generate mucosal respiratory pathogens. HIGHLIGHTS Saliva anti-spike were present > 90% participants 2022 clinically evident infections alone a weak inducer HCoV immunity correlates post-vaccine

Язык: Английский

Процитировано

2
Chronic Inflammatory Demyelinating Polyradiculoneuropathy with Diplopia Caused by an Alternative Coronavirus Disease 2019 Vaccine DOI Creative Commons
Satoshi Saito, Mutsumi Iijima, Misa Seki

и другие.

Case Reports in Neurological Medicine, Год журнала: 2024, Номер 2024(1)

Опубликована: Янв. 1, 2024

The etiology of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) remains elusive and is believed to involve multiple contributing factors. There have been cases linking CIDP the coronavirus disease 2019 (COVID‐19) mRNA vaccine. However, there are no documented instances following alternative vaccines. We report a case 48‐year‐old woman, previously vaccinated with Pfizer‐BioNTech’s COVID‐19 vaccine (BNT162b2), who subsequently received Moderna mRNA‐1273 Within 2 days postvaccination, she developed diplopia numbness in lower limbs’ distal extremities. Cerebrospinal fluid analysis exhibited protein‐cell dissociation, while F‐wave studies showed activity bilateral tibial nerves. Given disease’s progressive nature, patient was presumed commenced steroid pulse therapy intravenous immunoglobulin therapy. onset may be associated variations sequences constituents.

Язык: Английский

Процитировано

2
Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity DOI
Mario A. Ramírez, Ricardo A. Loaiza,

Yohana Martínez-Balboa

и другие.

Vaccine, Год журнала: 2024, Номер 42(23), С. 126203 - 126203

Опубликована: Авг. 22, 2024

Язык: Английский

Процитировано

2
Updated Considerations for the Immunopharmacological Aspects of the “Talented mRNA Vaccines” DOI Creative Commons
Cristiana Perrotta, Claudio Fenizia, Carla Carnovale

и другие.

Vaccines, Год журнала: 2023, Номер 11(9), С. 1481 - 1481

Опубликована: Сен. 12, 2023

Messenger RNA (mRNA) vaccines belong to a new class of medications, therapeutics, including both coding and non-coding RNAs. The use mRNA as therapy is based on the biological role itself, namely its translation into functional protein. goal produce specific antigen in cells elicit an immune response that might be prophylactic or therapeutic. potential vaccine has been envisaged for years but efficacy clearly demonstrated with approval COVID-19 2021. Since then, have pipeline diseases are still untreatable. There many advantages over traditional vaccines, easy cost-effective production, high safety, high-level expression. However, nature itself some technical issues pose challenges associated vaccines' development use. Here we review immunological pharmacological features by discussing their pharmacokinetics, mechanisms action, particular attention related administration. Furthermore, present overview areas application clinical trials utilize treatment.

Язык: Английский

Процитировано

5
Bacterial biopolymers in tissue engineering and regenerative medicine; current applications and future perspective DOI
Behnaz Bakhshandeh, Fatemeh Mohammadipanah, Mona Sadat Mirtaleb

и другие.

Biocatalysis and Agricultural Biotechnology, Год журнала: 2023, Номер 54, С. 102928 - 102928

Опубликована: Ноя. 1, 2023

Язык: Английский

Процитировано

4
COVID-19 mRNA vaccination during pregnancy does not harm syncytiotrophoblast development DOI Creative Commons
A. Jantine van Voorden, Christianne J.M. de Groot, Carrie Ris‐Stalpers

и другие.

International Journal of Infectious Diseases, Год журнала: 2024, Номер unknown

Опубликована: Янв. 1, 2024

IntroductionThe safety of COVID-19 mRNA vaccination during pregnancy is still a topic concern. The effects on placenta development have been poorly studied, even though correct essential for healthy outcomes. Here we investigated the effect maternal immune response to syncytiotrophoblast (STB), which forms functional cell layer where maternal-fetal exchange takes place.MethodsSerum samples were collected from pregnant women before and after second with Pfizer-BioNTech vaccine (n=12 paired samples). Human trophoblast stem cells subjected in vitro STB differentiation presence serum samples. Cell morphology, proliferation marker gene expression assessed determine extent differentiation.ResultsAll obtained an STB-like upregulated markers downregulated markers. We did not find any significant differences between STBs treated pre- post-vaccination samples.DiscussionThis study suggest that inflammatory SARS-CoV-2 antibodies blood are harmful placenta. These findings support growing body evidence safe.

Язык: Английский

Процитировано

1
mRNA vaccines in gastric cancer: How close are we? DOI
José Darío Portillo‐Miño,

David Bettin-Gonzalez,

Franco Andrés Montenegro Coral

и другие.

Vacunas (English Edition), Год журнала: 2024, Номер 25(1), С. 88 - 96

Опубликована: Янв. 1, 2024

Процитировано

1
Evaluating COVID-19 vaccine effectiveness during pre-Delta, Delta and Omicron dominant periods among pregnant people in the U.S.: Retrospective cohort analysis from a nationally sampled cohort in National COVID Collaborative Cohort (N3C) DOI Creative Commons
Qiuyuan Qin, Kenneth J. Wilkins, Sara Jones

и другие.

BMJ Public Health, Год журнала: 2024, Номер 2(1), С. e000770 - e000770

Опубликована: Июнь 1, 2024

To evaluate the effectiveness of COVID-19 vaccinations (initial and booster) during pre-Delta, Delta, Omicron dominant periods among pregnant people via (1) incident severe infections who were vaccinated vs. unvaccinated (2) post-COVID-19 vaccination breakthrough females non-pregnant.

Язык: Английский

Процитировано

1
COVID-19 : vaccination , therapeutics and a review of the science and public health DOI Open Access
Sanjit Kumar Shah, Kritick Bhandari,

Avish Shah

и другие.

Annals of Medicine and Surgery, Год журнала: 2024, Номер unknown

Опубликована: Июль 16, 2024

COVID-19, stemming from the SARS-CoV-2 virus, has initiated a worldwide respiratory pandemic. Remarkable headway been made in realm of vaccination, as nearly every nation COVID-19 vaccine deployment. However, mere 32.6% individuals low-income countries have received only single dose. Unprecedented research and development endeavors yielded over 170 vaccines, several which are now practical use. These vaccines demonstrated remarkable efficacy averting severe illness, hospitalization, fatalities even against emerging variants. Research pursuits persist, concentrating on novel technologies, oral nasal broader coronavirus protection, combinations. In therapeutics, there significant strides developing antiviral medications monoclonal antibodies. Nonetheless, challenges vaccination encompassing issues hesitancy, accessibility, financial barriers, knowledge gaps, logistical hindrances. Robust monitoring via global agencies reporting systems remains pivotal. Strategies for enhancing rooted fostering trust, countering misinformation, expanding access. As approach involves dedicated research, clinical trials, regulatory streamlining, stockpiling, international collaboration. Telemedicine public awareness campaigns play integral roles this effort, with coordination being linchpin preserving lives mitigating disease's impact. The campaign witnessed substantial advancements, an ongoing focus therapeutics that not more accessible affordable but also effective, particularly populations vulnerable communities.

Язык: Английский

Процитировано

1
Genomic insights into mRNA COVID-19 vaccines efficacy: Linking genetic polymorphisms to waning immunity DOI Creative Commons

Min-Jia Hsieh,

Ping‐Hsing Tsai,

Pin-Hsuan Chiang

и другие.

Human Vaccines & Immunotherapeutics, Год журнала: 2024, Номер 20(1)

Опубликована: Сен. 10, 2024

Genetic polymorphisms have been linked to the differential waning of vaccine-induced immunity against COVID-19 following vaccination. Despite this, evidence on mechanisms behind this and its implications for vaccination policy remains limited. We hypothesize that specific gene variants may modulate development vaccine-initiated immunity, leading impaired immune function. This study investigates genetic determinants influencing sustainability post-mRNA through a genome-wide association (GWAS). Utilizing hospital-based, test negative case-control design, we enrolled 1,119 participants from Taiwan Precision Medicine Initiative (TPMI) cohort, all whom completed full mRNA regimen underwent PCR testing during Omicron outbreak. Participants were classified into breakthrough protected groups based results. samples analyzed using SNP arrays with rigorous quality control. Cox regression identified significant single nucleotide (SNPs) associated infections, affecting 743 genes involved in processes such as antigenic protein translation, B cell activation, T Key include CD247, TRPV1, MYH9, CCL16, RPTOR, which are vital responses. Polygenic risk score (PRS) analysis revealed individuals higher PRS at greater infections post-vaccination, demonstrating high predictability (AUC = 0.787) validating population. finding confirms influence variations durability responses vaccine effectiveness. highlights importance considering evaluating proposes potential personalized strategies by tailoring regimens individual profiles.

Язык: Английский

Процитировано

1